{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:29:05Z","timestamp":1780662545514,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,28]]},"DOI":"10.7759\/cureus.100287","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T04:47:12Z","timestamp":1766983632000},"source":"Crossref","is-referenced-by-count":2,"title":["Cost Variation and Affordability of Oral Targeted Cancer Therapy in India: Comparison of Branded and Janaushadhi Products"],"prefix":"10.7759","author":[{"given":"Samiksha M","family":"Lohi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitali A","family":"Chindhalore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Dakhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehlata","family":"Gajbhiye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_1821_22","article-title":"Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India","volume":"156","author":"Sathishkumar K","year":"2022","unstructured":"Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India. Indian J Med Res. 2022, 156:598-607. 10.4103\/ijmr.ijmr_1821_22","journal-title":"Indian J Med Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09578-1","article-title":"Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program","volume":"22","author":"Kulothungan V","year":"2022","unstructured":"Kulothungan V, Sathishkumar K, Leburu S, et al.. Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program. BMC Cancer. 2022, 22:527. 10.1186\/s12885-022-09578-1","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20\u00a0years (2001-2020)","volume":"13","author":"Huang L","year":"2020","unstructured":"Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20\u00a0years (2001-2020). J Hematol Oncol. 2020, 13:143. 10.1186\/s13045-020-00977-0","journal-title":"J Hematol Oncol"},{"key":"ref5","article-title":"Protein kinase inhibitors and pathway-targeted small molecules","author":"Brunton LL","year":"2023","unstructured":"Brunton LL, Knollmann CB. Protein kinase inhibitors and pathway-targeted small molecules. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Wellstein A, Giaccone G (ed): McGraw-Hill, New York (NY); 2023. 14th Edition:1381-413."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26367","article-title":"Impact of the drug prices control order (2013) on the utilization of anticancer medicines in India: an interrupted time-series analysis","volume":"14","author":"Sharma B","year":"2022","unstructured":"Sharma B, Mehta A, Farooqui HH, Negandhi H, Selvaraj S. Impact of the drug prices control order (2013) on the utilization of anticancer medicines in India: an interrupted time-series analysis. Cureus. 2022, 14:e26367. 10.7759\/cureus.26367","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2016\/22384.8918","article-title":"Variation of cost among anti-cancer drugs available in Indian market","volume":"10","author":"Kolasani BP","year":"2016","unstructured":"Kolasani BP, Malathi DC, Ponnaluri RR. Variation of cost among anti-cancer drugs available in Indian market. J Clin Diagn Res. 2016, 10:FC17-20. 10.7860\/JCDR\/2016\/22384.8918","journal-title":"J Clin Diagn Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20191010","article-title":"Price variation in different brands of anticancer drugs available in Indian pharmaceutical market: a cost analysis study","volume":"1","author":"Adwal SK","year":"2019","unstructured":"Adwal SK, Baghel R. Price variation in different brands of anticancer drugs available in Indian pharmaceutical market: a cost analysis study. Int J Basic Clin Pharmacol. 2019, 1:642. 10.18203\/2319-2003.ijbcp20191010","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref9","article-title":"Variation in cost among anticancer drugs available in India: a cross-sectional study","volume":"1","author":"Patil RJ","year":"2023","unstructured":"Patil RJ, Bhandari PR, Gaiwale SD, et al.. Variation in cost among anticancer drugs available in India: a cross-sectional study. J Clin Diagn Res. 2023, 1:17.","journal-title":"J Clin Diagn Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_2387_22","article-title":"Cost analysis of anticancer chemotherapy and chemoirradiation regimens considering the drugs marketed through Jan Aushadhi (People's Medicine) stores and their branded counterparts: first cost comparison study","volume":"20","author":"Krishna A","year":"2024","unstructured":"Krishna A, Simon P, Palatty PL, Sacheendran D, Jayachandran M, George T, Baliga MS. Cost analysis of anticancer chemotherapy and chemoirradiation regimens considering the drugs marketed through Jan Aushadhi (People's Medicine) stores and their branded counterparts: first cost comparison study. J Cancer Res Ther. 2024, 20:1472-85. 10.4103\/jcrt.jcrt_2387_22","journal-title":"J Cancer Res Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.36468\/pharmaceutical-sciences.1473","article-title":"Analysis of the variation of costs in available anti-cancer drugs in the indian market","volume":"87(1)","author":"Patil R","year":"2025","unstructured":"Patil R, Bhandari P, Narwane S, et al.. Analysis of the variation of costs in available anti-cancer drugs in the indian market. Ind J Pharm Sci. 2025, 87(1):34-43. 10.36468\/pharmaceutical-sciences.1473","journal-title":"Ind J Pharm Sci"},{"key":"ref12","unstructured":"Current index of medical specialties. (2025). Accessed. September 27, 2025: https:\/\/www.mims.com\/india."},{"key":"ref13","unstructured":"Tata 1mg. (2025). Accessed. September 27, 2025: https:\/\/www.1mg.com\/."},{"key":"ref14","unstructured":"Apollo Pharmacy. (2025). Accessed. September 27, 2025: https:\/\/www.apollopharmacy.in\/."},{"key":"ref15","unstructured":"Pradhan Mantri Bhartiya Janaushadhi Pariyojana. (2025). Accessed. September 27, 2025: https:\/\/janaushadhi.gov.in\/productportfolio\/ProductviewList."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-001379","article-title":"Evaluating access to essential medicines for treating childhood cancers: a medicines availability, price and affordability study in New Delhi, India","volume":"4","author":"Faruqui N","year":"2019","unstructured":"Faruqui N, Martiniuk A, Sharma A, Sharma C, Rathore B, Arora RS, Joshi R. Evaluating access to essential medicines for treating childhood cancers: a medicines availability, price and affordability study in New Delhi, India. BMJ Glob Health. 2019, 4:e001379. 10.1136\/bmjgh-2018-001379","journal-title":"BMJ Glob Health"},{"key":"ref17","unstructured":"Press Note on Provisional Estimates of Annual Gross Domestic Product 2024-25 and Quarterly Estimates of GDP for Q4 2024-25. (2025). Accessed. September 27, 2025: https:\/\/mospi.gov.in\/sites\/default\/files\/press_release\/NAD_PR_30may2025.pdf."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.5983","article-title":"Real-world use of and spending on new oral targeted cancer drugs in the US, 2011-2018","volume":"181","author":"Fu M","year":"2021","unstructured":"Fu M, Naci H, Booth CM, et al.. Real-world use of and spending on new oral targeted cancer drugs in the US, 2011-2018. JAMA Intern Med. 2021, 181:1596-604. 10.1001\/jamainternmed.2021.5983","journal-title":"JAMA Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.909948","article-title":"National trends in the use of oral chemotherapy over 13 years","volume":"13","author":"Moreira A","year":"2022","unstructured":"Moreira A, Bernardo C, Ramos C, Aguiar P, Alves da Costa F. National trends in the use of oral chemotherapy over 13 years. Front Pharmacol. 2022, 13:909948. 10.3389\/fphar.2022.909948","journal-title":"Front Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone RM","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, et al.. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017, 377:454-64. 10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0741","article-title":"Targeted therapies, novel antibodies, and immunotherapies in advanced non-small cell lung cancer: clinical evidence and drug approval patterns","volume":"30","author":"Koban MU","year":"2024","unstructured":"Koban MU, Hartmann M, Amexis G, Franco P, Huggins L, Shah I, Karachaliou N. Targeted therapies, novel antibodies, and immunotherapies in advanced non-small cell lung cancer: clinical evidence and drug approval patterns. Clin Cancer Res. 2024, 30:4822-33. 10.1158\/1078-0432.CCR-24-0741","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 - common ground and common sense","volume":"13","author":"Senapati J","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023, 13:58. 10.1038\/s41408-023-00823-9","journal-title":"Blood Cancer J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-018-0406-6","article-title":"The impact of patent expiry on drug prices: a systematic literature review","volume":"16","author":"Vondeling GT","year":"2018","unstructured":"Vondeling GT, Cao Q, Postma MJ, Rozenbaum MH. The impact of patent expiry on drug prices: a systematic literature review. Appl Health Econ Health Policy. 2018, 16:653-60. 10.1007\/s40258-018-0406-6","journal-title":"Appl Health Econ Health Policy"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19231","article-title":"Generic anticancer drugs of the Jan Aushadhi scheme in India and their branded counterparts: the first cost comparison study","volume":"13","author":"George T","year":"2021","unstructured":"George T, Baliga MS.  Generic anticancer drugs of the Jan Aushadhi scheme in India and their branded counterparts: the first cost comparison study. Cureus. 2021, 13:e19231. 10.7759\/cureus.19231","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.628744","article-title":"Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: a systematic review of literature","volume":"9","author":"Ocran Mattila P","year":"2021","unstructured":"Ocran Mattila P, Ahmad R, Hasan SS, Babar ZU. Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: a systematic review of literature. Front Public Health. 2021, 9:628744. 10.3389\/fpubh.2021.628744","journal-title":"Front Public Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/442040-cost-variation-and-affordability-of-oral-targeted-cancer-therapy-in-india-comparison-of-branded-and-janaushadhi-products","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T04:47:14Z","timestamp":1766983634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/442040-cost-variation-and-affordability-of-oral-targeted-cancer-therapy-in-india-comparison-of-branded-and-janaushadhi-products"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.100287","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,28]]}}}